TY - JOUR
T1 - Long-term outcomes of non-ST-elevation myocardial infarction without creatine kinase elevation
T2 - The J-MINUET study
AU - J-MINUET investigators
AU - Ishihara, Masaharu
AU - Nakao, Koichi
AU - Ozaki, Yukio
AU - Kimura, Kazuo
AU - Ako, Junya
AU - Noguchi, Teruo
AU - Fujino, Masashi
AU - Yasuda, Satoshi
AU - Suwa, Satoru
AU - Fujimoto, Kazuteru
AU - Nakama, Yasuharu
AU - Morita, Takashi
AU - Shimizu, Wataru
AU - Saito, Yoshihiko
AU - Hirohata, Atsushi
AU - Morita, Yasuhiro
AU - Inoue, Teruo
AU - Okamura, Atsunori
AU - Uematsu, Masaaki
AU - Hirata, Kazuhito
AU - Tanabe, Kengo
AU - Shibata, Yoshisato
AU - Owa, Mafumi
AU - Tsujita, Kenichi
AU - Funayama, Hiroshi
AU - Kokubu, Nobuaki
AU - Kozuma, Ken
AU - Tobaru, Tetsuya
AU - Oshima, Shigeru
AU - Nakai, Michikazu
AU - Nishimura, Kunihiro
AU - Miyamoto, Yoshihiro
AU - Ogawa, Hisao
N1 - Publisher Copyright:
© 2017, Japanese Circulation Society. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Background: According to troponin-based criteria of myocardial infarction (MI), patients without elevation of creatine kinase (CK), formerly classified as unstable angina (UA), are now diagnosed as non-ST-elevation MI (NSTEMI), but little is known about their outcomes. Methods and Results: Between July 2012 and March 2014, 3,283 consecutive patients with MI were enrolled. Clinical follow-up data were obtained up to 3 years. The primary endpoint was a composite of all-cause death, non-fatal MI, non-fatal stroke, cardiac failure and urgent revascularization for UA. There were 2,262 patients with ST-elevation MI (STEMI), 563 NSTEMI with CK elevation (NSTEMI+CK) and 458 NSTEMI without CK elevation (NSTEMI-CK). From day 0, Kaplan-Meier curves for the primary endpoint began to diverge in favor of NSTEMI-CK for up to 30 days. The 30-day event rate was significantly lower in patients with NSTEMI-CK (3.3%) than in STEMI (8.6%, P<0.001) and NSTEMI+CK (9.9%, P<0.001). Later, the event curves diverged in favor of STEMI. The event rate from 31 days to 3 years was significantly lower in patients with STEMI (19.8%) than in NSTEMI+CK (33.6%, P<0.001) and NSTEMI-CK (34.2%, P<0.001). Kaplan-Meier curves from 31 days to 3 years were almost identical between NSTEMI+CK and NSTEMI-CK (P=0.91). Conclusions: Despite smaller infarct size and better short-term outcomes, long-term outcomes of NSTEMI-CK after convalescence were as poor as those for NSTEMI+CK and worse than for STEMI.
AB - Background: According to troponin-based criteria of myocardial infarction (MI), patients without elevation of creatine kinase (CK), formerly classified as unstable angina (UA), are now diagnosed as non-ST-elevation MI (NSTEMI), but little is known about their outcomes. Methods and Results: Between July 2012 and March 2014, 3,283 consecutive patients with MI were enrolled. Clinical follow-up data were obtained up to 3 years. The primary endpoint was a composite of all-cause death, non-fatal MI, non-fatal stroke, cardiac failure and urgent revascularization for UA. There were 2,262 patients with ST-elevation MI (STEMI), 563 NSTEMI with CK elevation (NSTEMI+CK) and 458 NSTEMI without CK elevation (NSTEMI-CK). From day 0, Kaplan-Meier curves for the primary endpoint began to diverge in favor of NSTEMI-CK for up to 30 days. The 30-day event rate was significantly lower in patients with NSTEMI-CK (3.3%) than in STEMI (8.6%, P<0.001) and NSTEMI+CK (9.9%, P<0.001). Later, the event curves diverged in favor of STEMI. The event rate from 31 days to 3 years was significantly lower in patients with STEMI (19.8%) than in NSTEMI+CK (33.6%, P<0.001) and NSTEMI-CK (34.2%, P<0.001). Kaplan-Meier curves from 31 days to 3 years were almost identical between NSTEMI+CK and NSTEMI-CK (P=0.91). Conclusions: Despite smaller infarct size and better short-term outcomes, long-term outcomes of NSTEMI-CK after convalescence were as poor as those for NSTEMI+CK and worse than for STEMI.
UR - http://www.scopus.com/inward/record.url?scp=85021405887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021405887&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-17-0033
DO - 10.1253/circj.CJ-17-0033
M3 - Article
C2 - 28320999
AN - SCOPUS:85021405887
SN - 1346-9843
VL - 81
SP - 958
EP - 965
JO - Circulation Journal
JF - Circulation Journal
IS - 7
ER -